Applied Clinical Trials-07-01-2010

Protecting Subjects: The IRBs Next Steps

SITES : Incorporating Standard of Care in Study Budgets Benefits of CTMS at the Investigative Site Also in this issue : FDA Transparency Efforts to Impact Research, Survey Assesses Europe?s Clinical Trials Directive, Tapping into the Potential of Pharmacists, Biosimilars Make Headway in the U.S.

Updates on Osteoporosis including Amgen and Prolia trials.

Personalized medicine enters the arena.

Act cover

Do Sites Prefer a Sponsor Company or CRO to Run Their Clinical Trial?

An overview of the clinical research landscape in this emerging region that also looks at its challenges.

Industry news focusing on the people and organizations who work in the clinical trials profession.

The verdict is awaited on the much criticized and long anticipated European clinical trials directive.

Survey reveals industry practices surrounding standard of care and insurance claims data.

The 12-year data exclusivity period has significant implications in delaying the launch of biosimilars.

More information may be available on drug applications to expand public understanding of FDA policies.

A recent survey indicates pharmacists should provide more clinical trial information to patients.

Clinical trial management systems seamlessly support enhanced financial productivity for sites.